We are live on ! Find out more
OAM

Oxford Asset Management Portfolio holdings

AUM $232M
1-Year Est. Return 31%
This Fund
S&P 500
This Quarter Est. Return
+6.67%
1 Year Est. Return
+31%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$4.64B
AUM Growth
-$549M
Cap. Flow
-$740M
Cap. Flow %
-15.94%
Top 10 Hldgs %
18.26%
Holding
2,053
New
548
Increased
435
Reduced
586
Closed
465

Sector Composition

Rank Sector Weight
1 Technology 14.84%
2 Communication Services 14.33%
3 Consumer Discretionary 13.23%
4 Healthcare 10.58%
5 Industrials 10.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
OPY icon
1076
Oppenheimer Holdings
OPY
$1.22B
$701K 0.02%
+25,771
New +$607K
CEVA icon
1077
CEVA Inc
CEVA
$992M
$700K 0.02%
15,218
-23,966
-61% -$1.1M
CPRX
1078
DELISTED
Catalyst Pharmaceutical
CPRX
$696K 0.02%
175,467
+37,138
+27% +$123K
ALTO icon
1079
Alto Ingredients
ALTO
$349M
$693K 0.01%
153,730
-164,991
-52% -$782K
WYNN icon
1080
Wynn Resorts
WYNN
$10.5B
$692K 0.01%
+4,122
New +$636K
MOFG
1081
DELISTED
MidWestOne Financial Group
MOFG
$691K 0.01%
20,343
-985
-5% -$34.8K
ADAP
1082
DELISTED
Adaptimmune Therapeutics
ADAP
$686K 0.01%
101,132
+55,894
+124% +$432K
LITS
1083
Lite Strategy Inc
LITS
$31.6M
$685K 0.01%
16,554
-6,588
-28% -$310K
GLRE icon
1084
Greenlight Captial
GLRE
$511M
$684K 0.01%
33,607
+15,332
+84% +$333K
CASC
1085
DELISTED
Cascadian Therapeutics, Inc.
CASC
$683K 0.01%
182,202
+46,165
+34% +$189K
PTGX icon
1086
Protagonist Therapeutics
PTGX
$9.4B
$680K 0.01%
+33,302
New +$591K
LRMR icon
1087
Larimar Therapeutics
LRMR
$436M
$679K 0.01%
12,174
-2,085
-15% -$94K
USNA icon
1088
Usana Health Sciences
USNA
$275M
$679K 0.01%
9,082
-15,957
-64% -$1.07M
AERI
1089
DELISTED
Aerie Pharmaceuticals
AERI
$679K 0.01%
11,265
-6,461
-36% -$392K
UBNK
1090
DELISTED
United Financial Bancorp, Inc.
UBNK
$677K 0.01%
38,159
+18,622
+95% +$339K
APA icon
1091
APA Corp
APA
$12.9B
$676K 0.01%
15,777
+5,106
+48% +$215K
CDR
1092
DELISTED
Cedar Realty Trust, Inc
CDR
$672K 0.01%
+16,705
New +$648K
DHC
1093
Diversified Healthcare Trust
DHC
$2.11B
$665K 0.01%
+34,544
New +$661K
CVGI icon
1094
Commercial Vehicle Group
CVGI
$148M
$663K 0.01%
62,004
+11,268
+22% +$108K
TRMB icon
1095
Trimble
TRMB
$13.6B
$662K 0.01%
16,147
-7,076
-30% -$290K
UNVR
1096
DELISTED
Univar Solutions Inc.
UNVR
$660K 0.01%
21,267
-13,720
-39% -$408K
TPB icon
1097
Turning Point Brands
TPB
$1.7B
$658K 0.01%
31,308
+19,781
+172% +$349K
LAUR icon
1098
Laureate Education
LAUR
$5.14B
$657K 0.01%
48,336
+22,843
+90% +$299K
NBR icon
1099
Nabors Industries
NBR
$1.23B
$652K 0.01%
+1,928
New +$614K
TRU icon
1100
TransUnion
TRU
$15.2B
$652K 0.01%
11,832
-30,486
-72% -$1.62M

Similar funds

Oxford Asset Management's Q4 2017 Portfolio in Review

As of Q4 2017, Oxford Asset Management held 2,053 positions worth $4.64B, down 11% from $5.19B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Oxford Asset Management withdrew a net $740M in Q4 2017, closing 465 positions and reducing 586 holdings. Its most notable exit was Rice Energy Inc., an estimated $166M position sold in full.

By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 15% a quarter earlier, followed by Communication Services and Consumer Discretionary.

Against the trend, Oxford Asset Management opened a new position in Cavium, Inc. worth $152M.

  • Oxford Asset Management's largest Q4 2017 buy was Cavium, Inc.: 1,791,008 shares worth $152M.
  • Oxford Asset Management added most to Akorn Inc in Q4 2017, an estimated $52.8M increase.
  • Oxford Asset Management's biggest Q4 2017 reduction was Altaba Inc, cutting an estimated $98.3M.
  • Oxford Asset Management fully exited Rice Energy Inc. in Q4 2017, selling an estimated $166M.
  • Oxford Asset Management's ten largest holdings make up 18% of its $4.64B portfolio in Q4 2017.
  • Oxford Asset Management opened 548 new positions and closed 465 in Q4 2017.
  • Oxford Asset Management's portfolio value fell 11% quarter-over-quarter to $4.64B.

Based on Oxford Asset Management's 13F filing for Q4 2017, filed 13 Feb 2018.